Thrombocytosis Phenotype in Prefibrotic Primary Myelofibrosis: Risk Stratification and Prognostic Significance.
High platelet counts in early myelofibrosis predict aggressive disease, giving doctors a simple way to identify patients needing closer monitoring.
In a 21-year retrospective cohort of 350 MPN patients, thrombocytosis within prefibrotic PMF independently predicts inferior overall survival with an HR of 7.80, supporting platelet count as a pragmatic risk stratifier to distinguish aggressive pre-PMF from essential thrombocythemia. These findings reinforce the clinical importance of integrated WHO-criteria histopathologic diagnosis and suggest thrombocytosis should prompt risk escalation in pre-PMF management.
What the study was
- Study design
- Retrospective cohort (competing-risk survival analysis)
- Population
- MPN patients (pre-PMF, ET, overt PMF) at Taipei Veterans General Hospital, 2002-2023
- Sample size
- 350
- Category
- Diagnostics
- Maturity
- Validated
- Journal
- Clinical Lymphoma Myeloma and Leukemia
Why it surfaced
Retrospective single-center study providing useful prognostic data for pre-PMF risk stratification, though design quality and novelty are limited. Clinically actionable finding (platelet count as risk stratifier) but well within current clinical intuition.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.